1 62

Nyrada Inc - Annual Report 2026

Contents 3
Corporate Directory 4
Chair’s Letter 5
Widening the Question 6
Protecting Innovation 6
A Pathway to the United States 6
Financial Strength and Discipline 6
Board and Governance 7
Looking Forward 7
CEO Report 8
Broadening the Pipeline 9
Regulatory Progress 9
Intellectual Property 9
Financial Summary 9
Looking Ahead 10
Directors’ Report 12
Directors 12
Company Secretary - David Franks 15
Principal activities 15
Significant changes in the state of affairs 15
Financial results 16
Review of operations 16
Completion of the Phase I clinical trial 16
PROTECT-MI Phase IIa clinical trial 16
Preclinical Research - Oncology 17
Preclinical Research - Neuroprotection 17
Regulatory Affairs 17
Intellectual Property 17
Corporate 17
Financial summary 18
Liquidity and capital resources 18
Matters subsequent to the end of the financial year 18
Future developments, prospects, and business strategies 18
Environmental regulation 18
Directors’ shareholdings 18
Unissued Common Stock 19
Dividends 20
Indemnity and insurance of officers 20
Indemnity and insurance of auditor 20
Meetings of Directors 21
Proceedings on behalf of the Company 21
Non-audit services 21
Auditor's independence declaration 21
Presentation currency 21
Jurisdiction of Incorporation 21
Corporate Governance Statement 22
Business Risks 22
(a) Uncertainty of clinical development 22
(b) Commercialisation 22
(c) Additional capital requirements 22
(d) Intellectual property rights 23
(e) Third party intellectual property infringement claims 23
(f) Risk of delay 24
Required statements 24
Remuneration report (audited) 25
Key Management Personnel 25
Remuneration Policy 25
Non-executive Director remuneration 26
Executive Director remuneration 26
Relationship between the remuneration policy and Consolidated Entity performance 27
Options Granted 28
Key terms of employment contracts 29
James Bonnar 29
Non-executive Directors 29
Key management personnel equity holdings 30
Shares of Nyrada Inc. 30
Options of Nyrada Inc. 31
Performance Shares 32
End of Remuneration report. 32
Auditor’s Independence Declaration 33
Independent Auditor’s Report 34
Consolidated statement of profit or loss and other comprehensive income 39
For the year ended 30 June 2026 39
Consolidated statement of financial position 40
As at 30 June 2026 40
Consolidated statement of changes in equity 41
For the year ended 30 June 2026 41
Consolidated statement of cash flows 42
For the year ended 30 June 2026 42
Notes to the consolidated financial statements 43
1. General information 43
2. Material accounting policy information 43
New or amended Accounting Standards and Interpretations adopted 43
Basis of preparation 43
Critical accounting estimates 43
Parent entity information 44
Income recognition 44
Interest 44
Government research and development tax incentives 44
Research and development expenditure 44
Share-based payments 44
3. Critical accounting judgements, estimates and assumptions 45
Government research and development tax incentives 45
Share-based payment transactions 45
Assessment of R&D expenditure not advancing to a stage of technical feasibility 46
4. Operating segments 46
5. Other income 46
6. Research and development grant income 46
7. Trade, other receivables and prepayments 46
8. Trade and other payables 46
9. Issued capital 47
Common stock 47
Performance Common Stock 47
10. Dividends 47
11. Unrecognised carry-forward tax losses 48
12. Parent entity information 48
Statement of profit or loss and other comprehensive income 48
Statement of financial position 48
Guarantees entered into by the parent entity in relation to the debts of its subsidiaries 48
Contingent liabilities 48
Capital commitments - Property, plant and equipment 48
Material accounting policy information 48
13. Subsidiaries 49
14. Events after reporting period 49
15. Cash flow information 49
Reconciliation of loss after income tax to net cash used in operating activities 49
Reconciliation of Cash 49
16. Share-based payments 50
17. Loss per share 52
18. Key Management Personnel disclosures 52
Compensation 52
19. Related party transactions 52
Key Management Personnel 52
20. Commitments and contingencies 53
21. Financial instruments 53
Capital management 53
Categories of financial instruments 53
Financial risk management objectives 53
Foreign currency risk 54
Liquidity risk management 54
22. Remuneration of auditors 54
Consolidated Entity Disclosure Statement 55
Basis of preparation 55
Determination of tax residency 55
Australian tax residency 55
Foreign tax residency 55
Partnerships and Trusts 55
Directors’ Declaration 56
Shareholder Information 57
Corporate Governance Statement 57
CHESS Depositary Interests 57
Distribution of CDIs 57
Unmarketable parcels 57
Unlisted securities 58
Distribution of Unlisted Securities (> 20% holding) 59
Voting rights 59
Required Statements 60
On-Market buy-back 60
Twenty (20) largest shareholders of quoted equity securities 60

RkJQdWJsaXNoZXIy MjE2NDg3